- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07863167
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
- Legemiddel: adebrelimab + SHR-A2009
- Legemiddel: adebrelimab + SHR-A2009
- Legemiddel: adebrelimab + SHR-A2009
- Legemiddel: paclitaxel or pemetrexed combined with carboplatin +adebrelimab
- Legemiddel: adebrelimab
- Legemiddel: adebeliizumab + SHR-A2009
- Legemiddel: adebeliizumab + SHR-A2009
- Legemiddel: adebeliizumab + platinum-containing double chemotherapy
- Legemiddel: almonertinib combined with SHR-A2009
- Legemiddel: almonertinib combined with SHR-A2009
- Legemiddel: almonertinib
- Legemiddel: SHR-A2009 combined with almonertinib
- Legemiddel: almonertinib monotherapy
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Yijing Chen
- Telefonnummer: 0518-82342973
- E-post: yijing.chen.yc510@hengrui.com
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510080
- Guangdong Provincial People's Hospital
-
Hovedetterforsker:
- Yilong Wu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
- At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
- The ECOG score was 0 or 1.
- Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
- Adequate bone marrow and organ function.
Exclusion Criteria:
- Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
- Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.
- Participants with active, known or suspected autoimmune diseases.
- Other malignant tumors within 5 years before screening.
- Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
- Participants with severe cardiovascular and cerebrovascular diseases.
- There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
- Arterial and venous thrombosis events occurred within 3 months before the first administration.
- HIV test positive.
- Participants with active hepatitis B or C.
1.Evidence of active tuberculosis infection within 1 year before the first administration.
12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.
14. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: group A1-1adebrelimab + SHR-A2009
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group A1-2 paclitaxel or pemetrexed combined with carboplatin +adebrelimab
|
paclitaxel or pemetrexed combined with carboplatin +adebrelimab |
|
Eksperimentell: group1 A2-1adebrelimab + SHR-A2009 (longer-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Eksperimentell: group2 A2-2adebrelimab + SHR-A2009 (shorter-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group A2-3 adebrelimab
|
adebrelimab |
|
Eksperimentell: group1 A3-1 adebeliizumab + SHR-A2009 (longer-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
Eksperimentell: group2 A3-2 adebeliizumab + SHR-A2009 (shorter-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group A3-3 adebeliizumab + platinum-containing double chemotherapy
|
adebeliizumab + platinum-containing double chemotherapy |
|
Eksperimentell: group B1-1 almonertinib combined with SHR-A2009 (longer-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
Eksperimentell: group B1-2 almonertinib combined with SHR-A2009 (shorter-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group B1-3 almonertinib
|
almonertinib |
|
Eksperimentell: group B2-1 SHR-A2009 combined with almonertinib
|
SHR-A2009 combined with almonertinib |
|
Aktiv komparator: group B2-2 almonertinib monotherapy
|
almonertinib monotherapy |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Part A1 : pCR rate;
Tidsramme: about 24 months
|
about 24 months
|
|
Part A2 : 2-year DFS rate;
Tidsramme: about 24 months
|
about 24 months
|
|
Part A3 : pCR rate and 18-month EFS rate;
Tidsramme: about 18 months
|
about 18 months
|
|
Part B1 : 2-year DFS rate.
Tidsramme: about 24 months
|
about 24 months
|
|
Part B2 : MPR rate.
Tidsramme: about 24 months
|
about 24 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The incidence and grade of adverse events;
Tidsramme: about 48 months
|
about 48 months
|
|
surgical complications;
Tidsramme: about 24 months
|
about 24 months
|
|
EFS
Tidsramme: about 24 months ;
|
about 24 months ;
|
|
ORR;
Tidsramme: about 24 months
|
about 24 months
|
|
DFS and DFS rates;
Tidsramme: about 24 months
|
about 24 months
|
|
OS ;
Tidsramme: about 48 months
|
about 48 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Lungesykdommer
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Lungeneoplasmer
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Karsinom, ikke-småcellet lunge
- Organiske kjemikalier
- Hydrokarboner
- Cycloparaffins
- Hydrokarboner, alicyklisk
- Hydrokarboner, syklisk
- Terpener
- Taxoider
- Cyclodecanes
- Diterpenes
- Paclitaxel
- Aumolertinib
Andre studie-ID-numre
- SHR-A2009-203
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .